Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)
Duloxetine
Product Images NDC 50090-2585
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-2585). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fig2 (Duloxetine Fig2)
Figure 3: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-1)
Figure 4: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-2)
The text is a graph showing the percentage of patients improved based on the level of pain improvement from baseline after taking Duloxetine 60mg twice a day, Duloxetine 60mg once a day, or placebo. The x-axis shows the percent improvement in pain from baseline while the y-axis shows the percentage of patients improved.*
Figure 7: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-1 (Duloxetine Fig5)
The text is a chart showing the percentage of patients' improvement in pain from baseline with Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. It also shows the percentage improvement in pain at different levels from baseline.*
Figure 8: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-3 (Duloxetine Fig6)
The text appears to be a chart or graph displaying different dosages of a medication called Duloxetine and the percentage of patients who experienced pain improvement from baseline. The chart shows that the higher the dosage of Duloxetine, the greater the percentage of patients who experienced improvement in pain. However, it is difficult to interpret the chart fully without additional context.*
Figure 9: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Oa-1 (Duloxetine Fig7)
This is a chart that displays the percentage of patients who experienced improvement in pain from baseline after receiving either a placebo or Duloxetine 60/120 mg once. The results are represented using a scale from 0 to 100, with 0 being no improvement and 100 being full improvement. The chart also includes a line graph showing the percent improvement in pain over time, with data points at specific time intervals.*
Duloxetine Fig8
This is a chart that shows the percentage of patients who experienced improvement in pain after taking a placebo or duloxetine (at a dosage of 60mg once daily) over a period of time. The chart also shows a scale of percent improvement in pain from baseline (BOCF) ranging from 0 to 100.*
Duloxetine Fig9
This appears to be a graph showing the percentage improvement of pain from baseline while using the medication Duloxetine at a dose of 60 or 120 mg once daily. However, without more context or clearer visuals it may be difficult to interpret the data accurately.*
Structure (Duloxetine Str)
Label Image (Lbl500902585)
Product No. 6492-0 is a box of 30 delayed-release capsules containing 60mg of Duloxetine, a medication commonly used to treat depression, anxiety, and chronic pain. It should be stored at a temperature of 68 to 77 degrees Fahrenheit (20 to 25 degrees Celsius).*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
